Home/Pipeline/INV461

INV461

Acute Myeloid Leukemia (AML)

DiscoveryActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Discovery

Status

Active

Company

invIOs

About invIOs

invIOs is a Vienna-based biotech developing novel immuno-oncology therapies, with a pipeline featuring both an autologous cell therapy platform (EPiC) and a small molecule program. Its lead asset, APN401, is in Phase 1 trials for solid tumors, while other programs target glioblastoma, AML, and enhanced CAR therapies. The company is privately held, raised a €8.2M Series A, and is led by a team with deep expertise in oncology drug development and Austrian biotech.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active